A share price of Mind Medicine Inc [MNMD] is currently trading at $12.62, up 3.02%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MNMD shares have gain 5.43% over the last week, with a monthly amount glided 32.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mind Medicine Inc [NASDAQ: MNMD] stock has seen the most recent analyst activity on October 13, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $28. On January 28, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $23 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $20 on December 20, 2024. ROTH MKM started tracking with a Buy rating for this stock on July 24, 2024, and assigned it a price target of $36. In a note dated May 29, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $27 on this stock.
Mind Medicine Inc experienced fluctuations in its stock price throughout the past year between $4.70 and $12.94. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Mind Medicine Inc [NASDAQ: MNMD] shares were valued at $12.62 at the most recent close of the market. An investor can expect a potential return of 121.87% based on the average MNMD price forecast.
Analyzing the MNMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.5 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mind Medicine Inc [NASDAQ:MNMD] is 4.98. In addition, the Quick Ratio stands at 4.98 and the Cash Ratio stands at 0.88.
Transactions by insiders
Recent insider trading involved Sullivan Mark, Chief Legal Officer, that happened on Sep 25 ’25 when 11278.0 shares were sold. Chief Executive Officer, Barrow Robert completed a deal on Sep 25 ’25 to sell 25797.0 shares. Meanwhile, Chief Medical Officer Karlin Daniel sold 7704.0 shares on Sep 25 ’25.
